# Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

> **NCT00743184** · PHASE2 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 28 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia (BPH)
- Lower Urinary Tract Symptoms (LUTS)

## Interventions

- **DRUG:** ozarelix
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00743184
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12-04
- **Primary completion:** 2010-01-20
- **Final completion:** 2010-01-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743184, "Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00743184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*